The rates of clinical and endoscopic recurrence in patients with Crohn's disease after first surgery according to different treatments and different studies are as follows: placebo 25% to 77%, 53% to 79%, 5-ASA 24% to 58%, 63% to 66%, budesonide 19% to 32%, 52% to 57%, nitroimidazoles 7% to 8%, 52% to 54%, thiopurines 34% to 50%, 42% to 44% and infliximab 0%, 9% which is the most effective.
Las tasas de recurrencia clínica y endoscópica, en pacientes con enfermedad de Crohn posterior a una primera cirugía, con los diferentes tratamientos y según diferentes estudios, son las siguientes, respectivamente: Placebo 25-77%, 53-79%, 5-ASA 24-58%, 63-66%, budesonida 19-32%, 52-57%, nitroimidazoles 7-8%, 52-54%, tiopurinas 34-50%, 42-44%, infliximab 0%,9%, siendo este último el más efectivo.